Introduction
Macrophage migration inhibitory factor (MIF) was discovered in 1966 by Bloom and Bennett as a cytokine that is implicated in the inhibition of macrophage motility. [1] Subsequently, MIF was also discovered to function as a hormone, a chemokine and as a molecular chaperone. Thus, MIF proved to be involved in various physiological and pathological processes. [2] [3] [4] Genetic deregulation of MIF (such as overexpression) has been implicated in many inflammatory and immune diseases in humans, such as diabetes, atherosclerosis and rheumatoid arthritis. [5] In addition, mounting evidence supports a role of MIF in tumorigenesis and progression. [6] Its key roles in health and disease raised interest in development of small molecule MIF modulators as potential therapeutics.
Many MIF functions are mediated by protein-protein interactions with membrane receptors. The cluster of differentiation 74 (CD74) receptor is the best characterized membrane receptor for MIF. [7] Recently, another membrane protein CD44 was reported as an integral component of the CD74 receptor complex, which is essential for MIF signal transduction. [8] By forming a complex with CD74 and CD44, MIF triggers activation of the mitogen activated protein kinase (MAPK) pathway. Activation of this pathway is associated with MIF mediated oncogenesis and inflammation. MIF functions in inflammation and immune cell chemotaxis are also mediated by interactions with chemokine receptors such as CXCR2 and CXCR4. [4] Besides extracellular functions, MIF is known to bind to intracellular protein targets such as Jun-activated domain-binding protein 1 (JAB1), which results in slowing down JAB1 mediated cell growth. [9] Therefore, development of molecules interrupting with MIF protein-protein interaction with extra-or intracellular targets has been emerging as an attractive strategy to block MIF signaling.
Prior evidence indicates that treatment with anti-MIF antibodies or small molecule MIF modulators enables disruption of MIF mediated functions. [10] Besides discovering a statistically significant up-regulation of MIF concentration in the blood of septic patients, Calandra et al. reported that an anti-MIF antibody can protect TNFα-deficient mice from fulminant septic shock. [11] Neutralization of MIF with antibodies also exhibited benefits on autoimmune encephalomyelitis [12] , endotoxic shock [13] and even cancer [14] . From the perspective of drug discovery, development of small molecule MIF binders has advantages compared to the development of antibodies. [15, 16] Many small molecule MIF binders have been discovered, but only a few of them have been tested for their biological activity. [17] [18] [19] Progression along this line is needed to shed light on the utility of MIF binders as a potential novel strategy for management of inflame diseases.
Normally, MIF exists in a homotrimeric form in which each monomer contains 115 amino acids and has a molecular mass of 12.4 kDa. [20] Apart from its functions in proteinprotein interactions, the MIF trimer also harbors keto-enol tautomerase activity. There are three tautomerase active sites in the MIF homotrimer, each located at the interface between two monomers, in which the residue Pro1 has a key role in catalysis. [21] Although, Ddopachrome and 4-hydroxyphenylpyruvate (4-HPP) were identified as substrates for the ketoenol tautomerase activity of MIF, the physiological role of this activity remains elusive.
Recent findings indicate that Tyr36, Lys66 and Asn109, which are located on the surface surrounding the catalytic site pocket of MIF, are involved in activation of CD74. [22] Besides, there is also a thiol-protein oxidoreductase (TPOR) active site located at the center of the enzyme, which is conferred by its Cys 57 -Ala-Leu-Cys 60 (CALC) motif. [23] Peptides containing the CALC region were reported to retain some biochemical properties of the fulllength MIF protein. [24] The structural correlations between its enzymatic activity and its physiological functions provide opportunities to develop small molecule inhibitors of the enzymatic activity that also modulate the physiological functions in which MIF is involved.
Although, the MIF tautomerase activity shows no direct correlation with its biological functions, the pocket that harbors this enzymatic activity has been employed for development of inhibitors that should ultimately interfere with MIF protein-protein interactions. [25] [26] [27] Inhibitors include the mostly investigated dopachrome analogue ISO-1, inhibitor Orita-13 and others ( Fig. 1 ).[28-31] Importantly, many previously described inhibitors have a nonreversible binding or a slow tight binding mode, [26] which obscures estimation of the equilibrium binding constants. Also direct measurement of the binding of compounds to the enzyme active site proved to be important to gain a realistic insight in the binding capacities of compounds that interfere with MIF tautomerase activity. [32] Recently, the Jorgensen group reported a series of competitive inhibitors of MIF tautomerase activity with a biaryltriazole structure for which they confirmed reversibility of binding. The K i value of the most potent compound, Jorgensen-3bb (( Fig. 1) , is 57 nM. [33] [34] [35] An interesting feature in their inhibitor collection is that adding a fluorine at the ortho-position of the phenolic hydroxyl group strongly favors inhibition. The highest potency was observed upon substitution on the triazole 4-position with a quinoline. However, this provides molecules with almost exclusively sp 2hybridized atoms and consequently a very flat molecular structure. This limits water solubility and potentially inhibitor selectivity. The availability of structural information for binding of this class of inhibitors to MIF provides a basis to explore the structure-activity relationships (SAR) further. computer-assisted search. Its K i value was reported to be 38 nM. [29] Jorgensen-3bb is one of the most potent inhibitors of MIF reported to date with a K i value of 57 nM. [34] Here we describe a SAR study for binding of the biaryltriazole-type of inhibitors to MIF. Using the triazole-phenol unit as a core, we have explored alternatives for the quinoline in the triazole 4-position in order to find inhibitors with a less planar structure. Firstly, we identified the interference of transition metals such as copper(II) or zinc(II) with MIF tautomerase activity, followed by optimizing the assay through addition of ethylenediaminetetraacetic acid (EDTA) to the assay buffer. Subsequently, we investigated a compound collection of 27 triazole-phenols that was assembled using the copper catalyzed alkyne to azide cycloaddition (CuAAC) reaction as a key step. Using this approach, we were able to identify novel triazole-phenols that reversibly inhibit MIF tautomerase activity and also provide activity on the cellular level.
Results and discussion

MIF tautomerase activity assay optimization
Recombinant human MIF was expressed and purified following methods published previously by our group [28] and others. [32] The MIF tautomerase activity assay using 4-HPP as a substrate ( Fig. 2A ) was established using previously described assay conditions. [30] To determine the IC 50 , the compounds were diluted from DMSO (20 µL) with water or water with 20 mM EDTA (10 µL) into a a 96 well plate. Subsequently, the dilutions were preincubated with the MIF enzyme solution (760 nM, 170 µL) for 15 minutes. The assay was started by mixing 50 µL of the inhibitor enzyme pre-incubation mixture with 50 µL of an aqeous 4-HPP (1.0 mM) solution. This provides a reaction mixture with 380 nM of the enzyme, 0.5 mM 4-HPP and various concentration of the inhibitor. In the positive control, MIF was incubated with a blanc DMSO dilution as a vehicle control before adding the 4-HPP substrate. In the negative control, the substrate was mixed with a blanc DMSO dilution in absence of MIF as an enzyme. In the negative control, the UV absorbance did not change over time, which was set to 0%, whereas the positive control was set to 100%.
To test the stability of MIF, 3 samples from the same batch of enzyme were stored at 4 ℃ for 1, 12 and 25 days, respectively, after being taken from the -80 ℃ freezer. Different storage times provide the same tautomerase activity levels (Fig. S1 ). In addition, unfolding temperatures of fresh enzyme and enzyme stored for 2 weeks in at 4 ℃ were determined by nanoDSF to be 77.9 ℃ and 78.9 ℃ (Fig. S1) . These results together show that MIF is stable upon prolonged storage at -80 ℃ or 4 ℃.
During our studies we noticed that irreproducible results from inhibitors synthesized using the CuAAC "click reaction" were obtained. This raised the idea that transition metals such as copper could influence the MIF tautomerase activity assay that we employed in our studies. To our surprise, we found that copper(II) inhibits MIF tautomerase activity with an IC 50 of 1.0 µM ( Fig. 2B) . Expanding on this finding we also found that zinc(II) inhibits MIF tautomerase activity with an IC 50 of 1.0 µM ( Fig. S3 ). This indicates that the observed inhibition does not depend on the redox potential of the transition metal but rather suggests a role for the metal ion as Lewis acid. These observations imply that presence of (traces of) transition metals could contribute to irregularities in MIF tautomerase inhibition assays. [36] Subsequently, we investigated the inhibition of MIF tautomerase activity by copper(II) further. In the regular assays, we apply MIF with a C-terminal His-tag. To test the influence of the His-tag, we used MIF without His-tag and found that the tautomerase activity of Histag free MIF was also completely blocked in presence of 20 µM copper(II) (Fig. S4) . In addition, we found that copper(II) also blocked the activity of a related enzyme, 4oxalocrotonate tautomerase (4-OT), in a Michael addition reaction ( Fig. S4 ). [37] In the literature, it has been reported that the copper(II)-containing protein ceruloplasmin (CP) can suppress MIF enzymatic activity, [38] which is in line with our findings here. Altogether, these findings indicate that the transition metals copper(II) and zinc(II) can interfere with the 4-HPP tautomerization reaction catalyzed by MIF under the assay conditions applied in this study.
We adjusted the assay conditions to prevent interference of transition metals with MIF tautomerase enzyme activity in inhibitor binding studies. Including ethylenediaminetetraacetic acid (EDTA) in the assay buffer proved to be an effective strategy to prevent interference of copper(II) with the MIF tautomerase activity. Our results indicate that 125 µM copper(II) has no effect on 4-HPP tautomerization by MIF if 0.5 mM EDTA is added to the assay buffer ( Fig.   2C ). Addition of EDTA did not influence the Km value for 4-HPP conversion as both conditions provided a Km of 1.1 mM in the Michealis-Menten enzyme kinetics ( Fig. S2) .
Based on these findings we included 0.5 mM EDTA in the MIF tautomerase assay buffer in our studies. This is particularly important for activity measurements of 4-(1,2,3triazole)phenols, as studied here, because their synthesis requires significant amounts of copper, which could result in the pollution of the final products.
We note that inhibition of MIF tautomerase activity by transition metals is the first time reported here, but that EDTA has already been used before in the assay buffer in MIF inhibitor development. [29, 39] However, in other studies, including those using CuAAC for inhibitor synthesis, did not apply EDTA in the assay buffer. [34, 35] Here we provide a rationale to include EDTA in the assay buffer in cases where the presence of traces of transition metals in the final products can be expected. 
Synthesis
A focused compound collection of 4-(1,2,3-triazole)phenol derivatives was obtained by coupling 4-azidophenol to various terminal alkynes using CuAAC (Scheme 1). In this study, the CuAAC reaction was performed by addition of a catalytic amount of CuSO 4 and sodium ascorbate in water to the alkyne and azide substrates dissolved in methanol. The reaction was allowed to proceed at room temperature or 60 ℃ for 12 hours. CuSO 4 (0.1 eq), sodium ascorbate (0.2 eq), MeOH, rt, overnight, 12-90%; iv. DCC, CH 3 CN, rt, 2h; v.
Pd, H 2 , rt, 4h, EtOH, 99%.
Enzyme inhibition study
The focused compound collection was screened for inhibition of MIF tautomerase activity by an assay employing 4-HPP as a substrate. The assay conditions, as described above, include 0.5 mM EDTA to avoid interference of residual copper(II) with the tautomerase activity. The inhibitors were screened for MIF binding by measurement of the residual MIF tautomerase activity in presence of 50 µM of the respective inhibitor. MIF tautomerase inhibitors ISO-1 and Jorgensen-2b were tested as a reference to literature values ( Table 1) . These inhibitors reduced the activity of MIF with percentages of 20% and 90% respectively at 50 µM, which is in line with their reported potency for MIF inhibition in literature. [34] Screening of the residual enzyme activity upon preincubation with 50 µM of the respective inhibitor provided clear structure-activity relationships for the three groups of 4-(1,2,3-triazole)phenol inhibitors as shown in Fig. 3 . For compounds of group A the residual enzyme activity is around 75% of the positive control for all inhibitors, which indicates a potency similar to ISO-1 without a clear structure-activity dependence. For group B the residual enzyme activity varies between 90% and 10% of the positive control, thus indicating a clear structure-activity dependence. Extending the 4-substitution of the 4-(1,2,3triazole)phenol scaffold from propyl to pentyl and 5-hexynyl reduces the residual enzyme activity from 90% to 10% of the control, whereas octyl substitution provides increases residual enzyme activity. This indicates that an aliphatic tail with 5 or 6 carbon atoms is optimal in this series of inhibitors. The structure-activity relationships for the compounds in group C are less clear with residual enzyme activities between 40 and 10% of the control with compound 7c as the most active one in this series. All the compounds that inhibited MIF tautomerase activity by more than 50% of the positive control were subjected for IC 50 determination. The IC 50 values are shown in Table 1 .
K i values are calculated by the Cheng-Prusoff equation: K i =IC 50 /(1+[S]/K M ) [41] in which K M = 1.1 mM. The K i value of ISO-1 was measured to be 44 ± 4.9 µM, which is in line with values reported in literature. [30] [36] To further confirm the validity of our assays and to enable direct comparison, inhibitor Jorgensen-2b and 3b were synthesized according to literature. [42] Using Jorgensen-2b we investigated the effect of addition of EDTA to the assay buffer on the IC 50 and K i values in the MIF inhibition assay. For Jorgensen-2b, a K i of 5.0±0.6 µM was determined in presence of 0.5 mM EDTA, whereas a K i value of 2.9±0.3 µM was determined in absence of 0.5 mM EDTA. This demonstrates that EDTA can influence the Ki values to a certain extend but that the observed differences in this case a limited to less than a two-fold change in potency. K i value of Jorgensen-3b was determined to be 0.42±0.03 µM with 0.5 mM EDTA presence. The K i values observed in our assay are in line with the K i of 8.8 and 0.59 µM for Jorgensen-2b and 3b, respectively, reported before by Jorgensen. [42] Compounds in group A were not subjected to IC 50 determinations due to a lack of inhibitory potency at concentrations of 50 µM. Group B provided two inhibitors with potencies in the low micromolar range. Compounds 5b and 7b had a K i of 6.9±0.3 µM and 6.5±0.8 µM, respectively. The clear activity dependence on the length of the aliphatic tail indicates a role for lipophilic interactions in binding. For group C, inhibitors with variant monocyclic aromatic groups exhibit K i values ranging from 19 to 35 µM. However, the bycyclic indole functionality provided stronger inhibition with a K i value of 6.9±0.5 µM for 7c. This could be due to both stacking and/or lipophilic interactions between the indole functionality of 7c and MIF. Extending the single carbon atom spacer between the triazole and the indole in 7c to a two-carbon atom spacer in 8c caused a loss of potency with a K i of 43±2.8 µM, which indicates a clear structure dependence of the activity. 
* Residual MIF tautomerase activityin presence of 50 µM inhibitor.
Inhibitor optimization and enzyme kinetic study
To further improve the inhibitory potency of the inhibitors identified against MIF, we substituted the phenolic ortho-position with a fluorine. [34] Therefore, two new inhibitors were synthesized as shown in Scheme 1D. The resulting compound 1d provided a K i of 3.2±0.3 µM, which is two times enhanced compared to its equivalent without fluorine 7c (Fig.   4A ). This proves again that an ortho-fluoro substitution is a favorable modification for triazole-phenol MIF inhibitors. By substitution of the 5-position of the indole in 1d with chlorine, inhibitor 2d was obtained, which proved to me more potent with a K i of 0.96 ± 0.2 µM. The solubility of 1d and 2d were respectively 24±0.19 (41.41±0.51 µM) and 10.8±0.10 µg/mL (28.01±0.26 µM) in pH 7.4 PBS buffer as measured by the shake-flask method (Fig.   S10 ). Both 1d and 2d have significantly improved aqueous solubility compared toinhibitor Jorgensen-3b, which is 2.2 µg/mL. [34] This demonstrates that reducing the planar character of inhibitors indeed improved water solubility. We note, however, that 2d did not dissolve completely at concentrations of 50 µM and higher, which prohibits measuring full inhibition in the enzyme inhibition study.
To investigate the mechanism of inhibition and to avoid artefacts as described previously, [25] the binding behavior of inhibitor 1d was characterized further. A preincubation and dilution assay was performed to study reversibility of 1d binding to MIF.
Towards this aim, MIF was pre-incubated with 83 µM of 1d for 10 minutes before 100-fold dilution and testing of the residual enzyme activity. Upon pre-incubation with 1d the MIF tautomerase activity could be fully recovered as compared to the positive control without inhibitor (Fig. 4B) . This indicates reversible binding for 1d.
The influence of inhibitor 1d on the enzyme kinetics of MIF-catalyzed conversion of 4-HPP was analyzed (Fig. 4C, 4D) . In presence of 2 or 5 µM 1d the K m increases from 1.14 to 1.60 and 1.95 µM respectively, whereas the V max remains constant between 0.24 and 0.29
(absorbance/min) compared to 0.27 for the control ( Table 2) . Thus, the enzyme kinetics demonstrate that 1d is a competitive inhibitor, which is consistent with previous reports for MIF inhibition by inhibitors with a triazole-phenol core. [34] Similar results were obtained for 2d as shown in the supporting information. The p-values show that the slopes are significantly non-zero (n=3, p-value < 0.05).
Binding affinity study
To confirm binding of 1d to MIF, we performed a microscale thermophoresis (MST) assay. MST is a newly emerging technology for analysis of binding to proteins. This technology exploits the ligand-induced changes in the molecular movement of fluorescently labeled proteins in a temperature gradient. [43] We determined the thermophoresis shift upon titration of different concentration of 1d to 50 nM MIF. The K D value was determined from the changes in thermal shifts upon titration of 1d, which provides an sigmoidal curve from which the binding affinity (K D ) was calculated to be 3.63 µM. Thus, the K D observed in the MST assay is comparable to the K i value of 3.2 µM calculated from the enzyme kinetic experiments (Fig. 5) . Altogether, we conclude that the 4-(1,2,3-triazole)phenol inhibitor 1d binds reversibly to MIF with a potency in the low micromolar range. 
Molecular modeling
Docking studies were performed to rationalize the structure-activity relationships observed for MIF inhibition. Structural information for the MIF interaction of the analogous biaryltriazoles was used as a basis for the molecular modeling (PDB code:4wrb and 5hvs ). [34] Modelling was performed using the software Discovery Fig. 6A, 6B, 6C) . A main difference is that the quinolone in Jorgensen-3bb occupies a position different from the indole 2-carboxamide functionality in 1d. The difference in potency could originate from the loss of stacking interactions between quinoline ring and residues Pro33 and Lys32 that convey a high potency to Jorgensen-3bb. Instead, 1d has a hydrogen bond with Lys32 and a hydrophobic interaction with Ile64. Although 1d does not reach the same potency as reported for Jorgensen-3bb, the interactions observed in the modelling appear to be useful because they enable targeting of a different part of the binding pocket.
The structure-activity relationship was further rationalized by investigating details from docking poses of 1d, 7c and 3c. The binding difference between 1d and 7c was a hydrogen bond could be found between the fluoro of 1d and residue Asn97, which was not existing for 7c. The extra hydrogen bond can contribute to the two-time enhancement of potency from 7c to 1d. Comparison was also made between 7c with the indole 2-carboxamide that provided a K i of 6.7 µM and 3c with a pyrrole 2-carboxamide that provided a K i of 29 µM (Fig. 6D, 6E) . The 4-fold change in potency between 3c and 7c could be attributed to hydrophobic interaction from Ile64. 
A549 cell colony formation assay and inhibition of ERK phosphorylation
MIF inhibitors have been shown to have inhibit the growth of A549 non-small cell lung cancer cells , in which MIF plays an essential role for anchorage-independent growth and invasive behavior. [44, 45] The growth inhibitory potency of 2d against A549 cells was To gain more insight into the effect of MIF inhibitors to tumor cell proliferation, phosphorylation of ERK is investigated in A549 cells. Towards this aim the cells are incubated with 2d or ISO-1 before treatment with rhMIF. Both 2d, as well as ISO-1, attenuate rhMIF induced ERK phosphorylation in A549 cell (Fig. 7B) . Thus inhibitor 2d is able to inhibit ERK phosphorylation and cell proliferation in A549 cells. ratio was applied to quantify pERK level (n=1, duplicates will be provided).
Conclusion
In this study, we investigated the structure-activity relationships for inhibition of MIF tautomerase activity by inhibitors with a 4-(1,2,3-triazole)-phenol core. During our studies we discovered that the transition metals copper(II) and zinc(II) inhibit MIF tautomerase activity with potencies in the low micromolar range. Addition of 0.5 mM EDTA to the assay buffer proved to be effective to avoid potential interferences from residual metal ions in inhibitor preparates. We aimed to replace the previously employed quinolone functionality by activity. In the negative control the enzyme was excluded to monitor non-catalyzed conversion of the substrate, which did not show a change in absorbance at 305 nm. Data from the first three minutes were used to calculate the initial velocities and the nonlinear regression analyses for the enzyme kinetics were repeated three times with the program Prism6 (GraphPad).
Docking study
Docking studies were performed to gain insight in the structure-activity relationships.
All molecular modelings were done with the program Discovery studio (Dassault systems) version 2018 and the crystal structures of human recombinant MIF (PDB-code:4wrb, [42] 5hvs [32] ) were used. The CDOCKER protocol was used for docking which is a CHARMM 
MST
MST experiments were performed on a Monolith NT.115 system (NanoTemper Technologies) using 100% LED and 20% IR-laser power. Laser on and off times were set at 30s and 5s, respectively. Recombinant His-tagged MIF was labeled with RED-tris-NTA for 30 minutes (NanoTemper Technologies) and applied at a final concentration of 50 nM. A two-fold dilution series was prepared for compound 1d in PBS-T with 5% DMSO.
Subsequently, 10 µL of labeled MIF was mixed with 10 µL samples with different concentration of compound 1d. Samples were filled into hydrophilic capillaries (Monolith NT.115 capillary, standard treated) for measurement.
Colony formation assay
A549 cells were seeded in 6-well plates, each well contained 2 mL medium with 200 A549 cells and incubated for 24 h. 10 mM ISO-1 or 2d were prepared by dissolving in DMSO. The inhibitors were diluted to different concentration in fresh medium before addition into the corresponding well upon which the cells were treated continuously for 10 days.
Finally, the cells were fixed with paraformaldehyde for 20 minutes and stained with crystal violet for 20 minutes. After washing, the image of each well was photographed and analyzed with ImageG. We defined one colony as an aggregate of >50 cells. The numbers of colonies was analyzed as the ratio of the numbers found in inhibitor treated samples compared to untreated samples.
ERK signaling pathway study
Cells were seeded into a 6-well plate at a density of 2x10 5 
